Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/11/20
End: 08/12/22
Due: 08/12/23
Phase: N/A
Priority: Normal
Start: 08/31/22
End: 09/30/25
Due: 09/30/26
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Phase: N/A
Priority: Normal
Start: 02/02/23
End: 05/01/26
Due: 05/01/27
Phase: N/A
Priority: Normal
Start: 01/11/22
End: 08/31/22
Due: 08/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients | NCT04458298 | Ashvattha Therapeutics, Inc. | user2@example.com | None | 2020-08-11 | 2022-08-12 | 2023-08-12 | - | - | 2025-07-14 |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | NCT05387837 | Ashvattha Therapeutics, Inc. | user2@example.com | None | 2022-08-31 | 2025-09-30 | 2026-09-30 | - | - | 2025-07-14 |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | NCT05395624 | Ashvattha Therapeutics, Inc. | user2@example.com | None | 2023-02-02 | 2026-05-01 | 2027-05-01 | - | - | 2025-07-14 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants | NCT05105607 | Ashvattha Therapeutics, Inc. | user2@example.com | None | 2022-01-11 | 2022-08-31 | 2023-08-31 | - | - | 2025-07-14 |